In this Timeline, we describe the characteristics of tumour antigens that are recognized by
spontaneous T cell responses in cancer patients and the paths that led to their identification …

Harnessing the immune system to eradicate malignant cells is becoming a most powerful
new approach to cancer therapy. FDA approval of the immunotherapy-based drugs …

Purpose: To elicit a long-lasting antitumor immune response, CD8+ and CD4+ T cells
should be activated. We attempted to isolate HLA-DR–presented peptides directly from …

Studies of the administration of interleukin-2 to patients with metastatic melanoma or kidney
cancer have shown that immunological manipulations can mediate the durable regression …

Dendritic cells (DCs) are considered to be promising adjuvants for inducing immunity to
cancer. We used mature, monocyte-derived DCs to elicit resistance to malignant melanoma …

Peptide vaccines incorporate one or more short or long amino acid sequences as tumor
antigens, combined with a vaccine adjuvant. Thus, they fall broadly into the category of …

Many antigens recognized by autologous T lymphocytes have been identified on human
melanoma. Melanoma patients usually mount a spontaneous T cell response against their …

The technological advances occurred in the last few years have led to a great increase in
the number of tumor associated antigens (TAA) that are currently available for clinical …

The first tumor‐specific shared antigens and the cancer‐germline genes that code for these
antigens were identified with antitumor cytolytic T lymphocytes obtained from cancer …

Defects in the major histocompatibility complex (MHC) class I antigen-processing machinery
(APM) have been described in tumors of different histology. Murine data suggest that defects …